Hepatectomy sequencing two vessels therapy for primary hepatocellular carcinoma
- VernacularTitle:肝切除序贯双管疗法治疗原发性肝癌
- Author:
Yize HU
;
De CHEN
;
Deji CHEN
;
Heping PENG
;
Jingtai LING
;
Yiwen DENG
;
Ping XUE
- Publication Type:Journal Article
- Keywords:
Liver neoplasms;
Hepatectomy;
Chemoembolization,therapeutic;
Chemotherapy,cancer,regional perfusion;
Hepatocellular
- From:
Cancer Research and Clinic
2008;20(7):452-453
- CountryChina
- Language:Chinese
-
Abstract:
Objective To summarize the experience of adjuvant therapy for primary hepatocellular carcinoma. Methods 316 cases of operable hepatocellular carcinoma were divided into three groups. Only hepatectomy were performed in group one (21 8cases).Preopemtive adjuvant TACE were done in group two (52 cases). Preoperative adjuvant TACE and postoperative trans-portal vein chemotherapy were done in group three (46 cases), which was named hepatectomy sequencing two vessel therapy. Results 1, 3 and 5 year survival rote were 51.2 %, 30.0 % and 20.5 % respectively in group one, 57.2 %, 43.0 % and 31.5 % in group two, 84.0 %, 62.5 % and 51.0 % in group three. The postoperative disease-free survival rate in group three was significantly higher than that in group one and group two (P ＜0.05). Conclusion Hepatectomy sequencing two vessels therapy in perioperative period might improve the survival rate, which can prevent and delay the incidence of recurrence and may improve the effect of liver resection.
